Characterization of a human bispecific antibody against CD20/CD55 for the treatment of burkitt lymphoma

被引：0
|
作者：
Macor, Paolo [1 ]
Mezzaroba, Nelly [1 ]
De Maso, Luca [1 ]
Garrovo, Chiara [2 ]
Biffi, Stefania [2 ]
Sblattero, Daniele [3 ]
Marzari, Roberto [1 ]
Tedesco, Francesco [1 ]
机构：
[1] Univ Trieste, Dept Life Sci, Trieste, Italy
[2] CBM, Opt Imaging Lab, Trieste, Italy
[3] Univ Piemonte Orientale, Dept Med Sci, Novara, Italy
来源：
IMMUNOBIOLOGY | 2012年 / 217卷 / 11期
关键词：
D O I：
10.1016/j.imbio.2012.08.060
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
59
引用
收藏
页码：1149 / 1150
页数：2
相关论文
共 50 条
  • [31] Pharmacodynamic Effects and Immune Correlates of Response to the CD20/CD3 Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Non-Hodgkin Lymphoma
    Hernandez, Genevive
    Huw, Ling-Yuh
    Belousov, Anton
    Wilson, Deanna
    Koeppen, Hartmut
    McCord, Ron
    Peng, Kun
    Bartlett, Nancy L.
    Budde, Lihua E.
    Assouline, Sarit
    Nastoupil, Loretta J.
    Yoon, Dok Hyun
    Matasar, Matthew J.
    Bender, Brendan
    Kwan, Antonia
    Li, Chi-Chung
    O'Hear, Carol
    Yin, Shen
    Wei, Michael C.
    Adamkewicz, Joanne I.
    BLOOD, 2019, 134
  • [32] Development and Characterization of a New Antipeptide Monoclonal Antibody Directed to Human CD20 Antigen
    Habibi-Anbouhi, Mahdi
    Azadmanesh, Kayhan
    Behdani, Mahdi
    Hajizadeh-Saffar, Ensiyeh
    Vahabpour, Rouhollah
    Shokrgozar, Mohammad Ali
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2015, 30 (07) : 310 - 316
  • [33] In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab
    Macor, Paolo
    Tripodo, Claudio
    Zorzet, Sonia
    Piovan, Erich
    Bossi, Fleur
    Marzari, Roberto
    Amadori, Alberto
    Tedesco, Francesco
    CANCER RESEARCH, 2007, 67 (21) : 10556 - 10563
  • [34] Neutralizing human antibodies against CD55 and CD59 targeted to lymphoma cells in vivo potentiate the therapeutic effect of Rituximab
    Macor, R.
    Piovan, E.
    Zorzet, S.
    Tripodo, C.
    Marzari, R.
    Amadori, A.
    Tedesco, F.
    MOLECULAR IMMUNOLOGY, 2007, 44 (1-3) : 212 - 212
  • [35] Effector mechanisms of a novel [CD16x(CD20)2]-directed bispecific antibody in vitro and in vivo
    Glorius, P.
    Baerenwaldt, A.
    Kellner, C.
    Staudinger, M.
    Parren, P. W. H., I
    van de Winkel, J. G. J.
    Humpe, A.
    Valerius, T.
    Repp, R.
    Nimmerjahn, F.
    Gramatzki, M.
    Peipp, M.
    ONKOLOGIE, 2010, 33 : 97 - 97
  • [36] EXPRESSION OF THE COMPLEMENT REGULATORY PROTEINS CD21, CD55 AND CD59 ON BURKITT-LYMPHOMA LINES - THEIR ROLE IN SENSITIVITY TO HUMAN SERUM-MEDIATED LYSIS
    KURAYA, M
    YEFENOF, E
    KLEIN, G
    KLEIN, E
    EUROPEAN JOURNAL OF IMMUNOLOGY, 1992, 22 (07) : 1871 - 1876
  • [37] Measuring CD20 binding for humanization of anti-CD20 antibody
    Meng, YJG
    Hong, K
    Presta, L
    Penn, A
    Adams, C
    Chuntharapai, A
    Yang, JH
    Lu, YM
    Wong, WL
    FASEB JOURNAL, 2004, 18 (04): : A59 - A59
  • [38] Development of a novel bispecific antibody targeting PD-L1 and CD55 for cancer therapy.
    Chaudhary, Amit K.
    Shi, Jiadong
    Cai, Wenyan
    Wang, Bo
    Zaman, Mohd S.
    Huang, Cai
    Lin, Jun
    Kan, Steven Z.
    Zhou, Joe
    Dong, Jianbo
    Liu, Yue
    CANCER RESEARCH, 2021, 81 (13)
  • [39] Expression of CD55, CD46 and CD59 in human tissues
    Horsley, J
    Atkinson, C
    Wallwork, J
    Goddard, M
    XENOTRANSPLANTATION, 2001, 8 : 65 - 66
  • [40] Unique molecular recognition of CD20 by the type II CD20 antibody GA101
    Niederfellner, G. J.
    Lammens, A.
    Georges, G. J.
    Schwaiger, M.
    Franke, A.
    Wiechmann, K.
    Moessner, E.
    Umana, P.
    Hopfner, K. P.
    Klein, C.
    EJC SUPPLEMENTS, 2010, 8 (07): : 75 - 76
12345